Trends in pancreatic adenocarcinoma incidence and mortality in the United States in the last four decades; a SEER-based study

Anas M Saad, Tarek Turk, Muneer J Al-Husseini, Omar Abdel-Rahman, Anas M Saad, Tarek Turk, Muneer J Al-Husseini, Omar Abdel-Rahman

Abstract

Background: Pancreatic cancer is the fourth-leading cause of cancer deaths in the United States. The silent nature of the disease and its poor prognosis, the need for further research, along with the need to assess the outcomes of current approaches necessitate an ongoing evaluation of the epidemiology and mortality-trends of this malignancy. Continuous monitoring of disease-patterns, on population-levels, may help scientists assess the quality of healthcare delivery, boost their understanding of diseases' characteristics and risk factors, and detect gaps whereby further research is needed. None of the previous reports shed light on pancreatic adenocarcinomas (PAC), the most common type of Pancreatic Cancer, as the primary outcome. In this study we aim to investigate PAC's incidence and mortality trends over the last four decades in the United States.

Methods: We used SEER 9 database to study PAC cases during 1974-2014. Incidence and mortality rates were calculated by sex, age, race, state and stage of PAC. Annual percent change (APC) was calculated using joinpoint regression software.

Results: We reviewed 67,878 PAC cases; most of these cases were in the head of pancreas. Overall PAC incidence rates increased 1.03% (95% CI, 0.86-1.21, p <.001) per year over the study period. Rates of adenocarcinoma of the head of pancreas increased 0.87% (95% CI, 0.68-1.07, p <.001), and rates of adenocarcinoma of the body and tail of pancreas increased 3.42% (95% CI, 3.06-3.79, p <.001) per year during 1973-2014. PAC incidence-based mortality increased 2.22% (95% CI, 1.93-2.51, p <.001) per year. However, during 2012-2014 there was a statistically significant decrease in PAC incidence-based mortality; APC, -24.70% (95% CI, -31.78 - -16.88, p <.001).

Conclusion: PAC's incidence and mortality rates have been increasing for decades. However, the last few years have shown a promising decrease in mortality. We believe that further advances in healthcare delivery and research can lead to a further mortality decrease. Future studies can use this paper as a baseline to keep monitoring the outcomes of PAC's therapy.

Keywords: Incidence; Mortality; Pancreatic adenocarcinoma; SEER.

Conflict of interest statement

Ethics approval and consent to participate

We got approval from the National Cancer Institute to use data of patient from SEER database. Participant consent was not necessary as this study involved the use of a previously-published de-identified database according to SEER database.

Consent for publication

Not applicable

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Trends in annual pancreatic adenocarcinoma incidence; a according to subsite; b according to stage among pancreatic head tumors; c according to stage among pancreatic body and tail tumors
Fig. 2
Fig. 2
Trends in annual pancreatic adenocarcinoma incidence-based mortality; a according to subsite; b according to stage among pancreatic head tumors; c according to stage amog pancreatic body and tail tumors

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30. doi: 10.3322/caac.21442.
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA: a cancer journal for clinicians. 2016;66(1):7–30.
    1. National Cancer Institute. Estimated new cancer cases and deaths for 2013. SEER (Surveillance Epidemiology and End Results) cancer statistics review. Available from: .
    1. De La Cruz M, Young AP, Ruffin MT. Diagnosis and management of pancreatic cancer. Am Fam Physician. 2014;89(8):626–632.
    1. Mohammed S, George Van Buren I, Fisher WE. Pancreatic cancer: advances in treatment. World Journal of Gastroenterology: WJG. 2014;20(28):9354.
    1. National Research Council (US) Committee on Future Directions for Behavioral and Social Sciences Research at the National Institutes of Health; Singer BH, Ryff CD, editors. New Horizons in Health: An Integrative Approach. Washington (DC): National Academies Press (US); 2001. 8, Population Perspectives: Understanding Health Trends and Evaluating the Health Care System. Available from: .
    1. Pearce N. Epidemiology as a population science. Int J Epidemiol. 1999;28(5):S1015. doi: 10.1093/oxfordjournals.ije.a019904.
    1. Lau MK, Davila JA, Shaib YH. Incidence and survival of pancreatic head and body and tail cancers: a population-based study in the United States. Pancreas. 2010;39(4):458–462. doi: 10.1097/MPA.0b013e3181bd6489.
    1. Zhang J, Dhakal I, Yan H, et al. Trends in pancreatic cancer incidence in nine SEER Cancer Registries, 1973–2002. Annals of oncology. 2007;18(7):1268–1279. doi: 10.1093/annonc/mdm123.
    1. Surveillance Research Program, National Cancer Institute SEER*Stat software () version 8.3.4.
    1. Surveillance, Epidemiology, and End Results (SEER) Program () SEER*Stat Database: Incidence - SEER 9 Regs Research Data, Nov 2016 Sub (1973-2014) <Katrina/Rita Population Adjustment> - Linked To County Attributes - Total U.S., 1969-2015 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2017, based on the November 2016 submission.
    1. Chu KC, Miller BA, Feuer EJ, et al. A method for partitioning cancer mortality trends by factors associated with diagnosis: An application to female breat cancer. J Clin Epidemiol. 1994;47(12):1451–1461. doi: 10.1016/0895-4356(94)90089-2.
    1. Joinpoint Regression Program, Version 4.5.0.1. June, 2017; Statistical Research and Applications Branch, National Cancer Institute. . Last Accessed on 26/7/2017.
    1. Kim H-J, Fay MP, Feuer EJ, et al. Permutation tests for joinpoint regression with applications to cancer rates. Statistics in medicine. 2000;19(3):335–351. doi: 10.1002/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>;2-Z.
    1. Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med. 2014;371(11):1039–1049. doi: 10.1056/NEJMra1404198.
    1. Zheng T, Holford TR, Ward BA, et al. Time trend in pancreatic cancer incidence in Connecticut, 1935–1990. Int J Can. 1995;61(5):622–627. doi: 10.1002/ijc.2910610507.
    1. Wood H, Gupta S, Kang J, et al. Pancreatic cancer in England and Wales 1975–2000: patterns and trends in incidence, survival and mortality. Aliment Pharmacol Ther. 2006;23(8):1205–1214. doi: 10.1111/j.1365-2036.2006.02860.x.
    1. Levi F, Lucchini F, Negri E, et al. Pancreatic cancer mortality in Europe: the leveling of an epidemic. Pancreas. 2003;27(2):139–142. doi: 10.1097/00006676-200308000-00006.
    1. Pericleous M, Rossi RE, Mandair D, et al. Nutrition and pancreatic cancer. Anticancer Res. 2014;34(1):9–21.
    1. Conroy T, Desseigne F, Ychou M, et al. Randomized phase III trial comparing FOLFIRINOX (F: 5FU/leucovorin [LV], irinotecan [I], and oxaliplatin [O]) versus gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA): preplanned interim analysis results of the PRODIGE 4/ACCORD 11 trial. J Clin Oncol. 2010;28(15_suppl):4010-4010.
    1. Lowenfels AB, Maisonneuve P. Epidemiology and risk factors for pancreatic cancer. Best Pract Res Clin Gastroenterol. 2006;20(2):197–209. doi: 10.1016/j.bpg.2005.10.001.
    1. Lin Y, Tamakoshi A, Kawamura T, et al. A prospective cohort study of cigarette smoking and pancreatic cancer in Japan. Cancer Causes and Control. 2002;13(3):249–254. doi: 10.1023/A:1015052710213.
    1. Iodice S, Gandini S, Maisonneuve P, et al. Tobacco and the risk of pancreatic cancer: a review and meta-analysis. Langenbeck's Archives of Surgery. 2008;393(4):535–545. doi: 10.1007/s00423-007-0266-2.
    1. de Gonzalez AB, Sweetland S, Spencer E. A meta-analysis of obesity and the risk of pancreatic cancer. Br J Cancer Suppl. 2003;89(3):519. doi: 10.1038/sj.bjc.6601140.
    1. Risch HA, Lu L, Kidd MS, Wang J, Zhang W, Ni Q, Gao YT, Yu H. Helicobacter pylori seropositivities and risk of pancreatic carcinoma. Biomarkers & Prevention: Cancer Epidemiology; 2014.
    1. Schulte A, Pandeya N, Fawcett J, Fritschi L, Risch HA, Webb PM, Whiteman DC, Neale RE. Association between Helicobacter pylori and pancreatic cancer risk: a meta-analysis. Cancer Causes & Control. 2015; 10.1007/s10552-015-0595-3.
    1. Artinyan A, Soriano PA, Prendergast C, et al. The anatomic location of pancreatic cancer is a prognostic factor for survival. HPB. 2008;10(5):371–376. doi: 10.1080/13651820802291233.
    1. Barreto SG, Shukla PJ, Shrikhande SV. Tumors of the Pancreatic Body and Tail. World J Oncol. 2010; 10.4021/wjon2010.04.200w.
    1. James BYM, Gross CP, Wilson LD, et al. NCI SEER public-use data: applications and limitations in oncology research. Oncology. 2009;23(3):288.
    1. Noone A-M, Lund JL, Mariotto A, et al. Comparison of SEER treatment data with Medicare claims. Medical care. 2016;54(9):e55. doi: 10.1097/MLR.0000000000000073.
    1. Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer research. 2014;74(11):2913–2921. doi: 10.1158/0008-5472.CAN-14-0155.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다